MLYS

Mineralys Therapeutics Inc

Add to Watchlist

Advanced Chart

37.485

-0.175(-0.465%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

38.750

Open

38.050

VWAP

38.00

Vol

635.83K

Mkt Cap

2.83B

Low

37.460

Amount

24.16M

EV/EBITDA(TTM)

Total Shares

49.65M

2.52B

EV/OCF(TTM)

P/S(TTM)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.636

-43.74%

-0.619

-36.88%

-0.547

-30.8%

Estimates Revision

Stock Price

Go Up

+168.71%

In Past 3 Month

7 Analyst Rating

15.09% Upside

Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 43.14 USD with a low forecast of 26.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

15.09% Upside

Current: 37.485

Low

26.00

Averages

43.14

High

52.00

15.09% Upside

Current: 37.485

Low

26.00

Averages

43.14

High

52.00

Wells Fargo

Overweight

upgrade

$26 -> $50

2025-09-11

Reason

Wells Fargo

Price Target

$26 -> $50

2025-09-11

upgrade

Overweight

Reason

Wells Fargo raised the firm's price target on Mineralys Therapeutics to $50 from $26 and keeps an Overweight rating on the shares, reflecting increased probability in hypertension and confidence in competitive positioning. The firm sees the investment thesis revolving more around the M&A case over the next few quarters.

Jefferies

Hold

initiated

$15

2025-06-10

Reason

Jefferies

Price Target

$15

2025-06-10

initiated

Hold

Reason

Jefferies initiated coverage of Mineralys Therapeutics (MLYS) with a Hold rating and $15 price target. Mineralys has a clinically derisked and novel "$1B-plus blood pressure pill" for which the firm expects the company to file for approval in 2026. Consensus assumes $1B in sales in 2033, but the firm's estimate is about 40%-50% lower due to access and competition from AstraZeneca (AZN). Upside potential can be debated if Mineralys finds a partner to accelerate the launch, but it is "hard to handicap the economics at this point and would take away a near term M/A scenario," the analyst added.

Guggenheim

Seamus Fernandez

Buy

downgrade

$52 -> $48

2025-05-14

Reason

Guggenheim

Seamus Fernandez

Price Target

$52 -> $48

2025-05-14

downgrade

Buy

Reason

Guggenheim analyst Seamus Fernandez lowered the firm's price target on Mineralys Therapeutics to $48 from $52 and keeps a Buy rating on the shares. The firm, which is updating its model after Q1 earnings and catching up with management, says results were "largely incremental," but highlights that Mineralys expects to have a pre-NDA meeting with the FDA in Q4 to ensure the agency and the company are aligned on expectations for the NDA package for lorundrostat.

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Maintains

$30 → $42

2025-04-02

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$30 → $42

2025-04-02

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$30

2025-03-10

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$30

2025-03-10

Reiterates

Strong Buy

Reason

Guggenheim

Seamus Fernandez

Strong Buy

Reiterates

n/a

2025-02-24

Reason

Guggenheim

Seamus Fernandez

Price Target

n/a

2025-02-24

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Mineralys Therapeutics Inc (MLYS.O) is -15.88, compared to its 5-year average forward P/E of -4.61. For a more detailed relative valuation and DCF analysis to assess Mineralys Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.61

Current PE

-15.88

Overvalued PE

-1.97

Undervalued PE

-7.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.05

Undervalued EV/EBITDA

-6.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00